Key members of the House and Senate Appropriations committees issued statements on Monday, September 21, 2026, opposing a reported White House plan to increase political oversight of the National Institutes of Health (NIH) grant-making process. Sen. Susan Collins (R-Maine), chair of the Senate panel, and Sen. Patty Murray (D-Wash.), the ranking member, along with Rep. Rosa DeLauro (D-Conn.), stated that the proposal would shift authority away from scientific experts toward political appointees. The lawmakers argued that the Office of Management and Budget (OMB) should not be involved in individual agency grant decisions.
The opposition follows reports on Friday, September 18, 2026, that administration officials, including OMB Director Russell Vought, met with President Trump to discuss an executive order. The proposed order would reportedly create a committee with the power to review and potentially veto grants awarded by the NIH, which is the nation’s largest funder of biomedical research. Vought has criticized the agency for funding projects he characterized as "woke" initiatives that conflict with the administration's agenda, including an executive order barring "equity-related" grants.
NIH Director Jay Bhattacharya reportedly defended the agency’s merit-based peer-review process during the Friday meeting. This conflict follows previous tensions between the administration and Congress over NIH funding, including a proposed 15 percent cap on indirect research costs and delays in the disbursement of funds previously approved by lawmakers. While the White House has not yet issued the reported executive order, health care advocacy groups and university leaders have joined lawmakers in expressing concern that changing the approval process could stall medical research.
For researchers and patients, the scale of the impact involves billions of dollars in annual funding that supports thousands of projects at hospitals and universities in every state. A report indicated the administration has already cut or frozen $177 billion in grants across various agencies. If specific NIH grants are terminated or blocked for non-scientific reasons, as occurred when the administration terminated some diversity-related grants in 2025, researchers would see immediate halts to their funding, potentially ending years-long clinical trials or laboratory studies before completion.
The dispute also sets a precedent for how federal agencies operate independently of the White House. Congressional leaders argue the move violates their intent, as they recently passed a government funding measure on September 2, 2026, that blocked a similar OMB rule through December. The knock-on effects could include legal challenges regarding the separation of powers and the authority of the executive branch to override congressional appropriations. The current funding block remains in effect until December 2026, creating a deadline for the administration to either issue a new executive order or wait for the legislative restriction to expire.